Boosting anticancer immunotherapy through androgen receptor blockade

Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8(+) T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.

Automated summary

Androgen receptor negatively modulates CD8(+) T cell-driven antitumor immune response, and targeting the androgen-axis blockade may improve the activity of ICIs in CRPC.